Management options in multiple sclerosis-associated fatigue

Bibliography

• Compston A, Coles A. Multiple sclerosis. Lancet 2008;372(9648):1502-17
   PubMed Web of Science ®Google Scholar
• Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler 2003;13(3):219-27
   Web of Science ®Google Scholar
• Kos D, Kerckhofs E, Nagels G, Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 2008;22(1):91-100
   PubMed Web of Science ®Google Scholar
• Amato MP, Zipoli V, Goretti B, Benign multiple sclerosis: cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006;253(8):1054-9
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A, Cognitive and psychosocial features of childhood and juvenile MS. Neurology 2008;70(20):1891-7
   PubMed Web of Science ®Google Scholar
• Amato MP, Goretti B, Ghezzi A, Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up. Neurology 2010;75(13):1134-40
   PubMed Web of Science ®Google Scholar
• Flachenecker P, Meissner H. Fatigue in multiple sclerosis presenting as acute relapse: subjective and objective assessment. Mult Scler 2008;14(2):274-7
   Google Scholar
• Simmons RD, Tribe KL, McDonald EA. Living with multiple sclerosis: longitudinal changes in employment and the importance of symptom management. J Neurol 2010;257(6):926-36
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis for Clinical Practice Guidelines. Fatigue and Multiple Sclerosis: Evidence-Based Management Strategies for Fatigue in Multiple Sclerosis; 1998.
   Google Scholar
• Kent-Braun JA, Sharma KR, Weiner MW, Miller RG. Effects of exercise on muscle activation and metabolism in multiple sclerosis. Muscle Nerve 1994;17(10):1162-9
   PubMed Web of Science ®Google Scholar
• Sandroni P, Walker C, Starr A. ‘Fatigue’ in patients with multiple sclerosis. Motor pathway conduction and event-related potentials. Arch Neurol 1992;49(5):517-24
   PubMedGoogle Scholar
• Roelcke U, Kappos L, Lechner-Scott J, Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48(6):1566-71
   PubMed Web of Science ®Google Scholar
• Comi G, Leocani L, Rossi P, Colombo B. Physiopathology and treatment of fatigue in multiple sclerosis. J Neurol 2001;248(3):174-9
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA, Colombo B, Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002;15(3):559-67
   PubMed Web of Science ®Google Scholar
• Pellicano C, Gallo A, Li X, Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Arch Neurol 2010;67(4):447-53
   PubMedGoogle Scholar
• Garland SJ, Lavoie BA, Brown WF. Motor control of the diaphragm in multiple sclerosis. Muscle Nerve 1996;19(5):654-6
   PubMed Web of Science ®Google Scholar
• Djaldetti R, Ziv I, Achiron A, Melamed E. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology 1996;46(3):632-5
   PubMed Web of Science ®Google Scholar
• Sheean GL, Murray NM, Rothwell JC, An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997;120(Pt 2):299-315
   PubMedGoogle Scholar
• Dickinson CJ. Chronic fatigue syndrome–aetiological aspects. Eur J Clin Invest 1997;27(4):257-67
   PubMed Web of Science ®Google Scholar
• Gottschalk M, Kumpfel T, Flachenecker P, Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol 2005;62(2):277-80
   PubMedGoogle Scholar
• Heesen C, Nawrath L, Reich C, Fatigue in multiple sclerosis: an example of cytokine mediated sickness behaviour? J Neurol Neurosurg Psychiatry 2006;77(1):34-9
   PubMed Web of Science ®Google Scholar
• Rice CL, Vollmer TL, Bigland-Ritchie B. Neuromuscular responses of patients with multiple sclerosis. Muscle Nerve 1992;15(10):1123-32
   PubMed Web of Science ®Google Scholar
• Keselbrener L, Akselrod S, Ahiron A, Is fatigue in patients with multiple sclerosis related to autonomic dysfunction? Clin Auton Res 2000;10(4):169-75
   PubMed Web of Science ®Google Scholar
• Sharma KR, Kent-Braun J, Mynhier MA, Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve 1995;18(12):1403-11
   PubMed Web of Science ®Google Scholar
• Hohn O, Strohschein K, Brandt AU, No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One 2010;5(12):e15632
   PubMed Web of Science ®Google Scholar
• Bol Y, Duits AA, Lousberg R, Fatigue and physical disability in patients with multiple sclerosis: a structural equation modeling approach. J Behav Med 2010;33(5):355-63
   PubMed Web of Science ®Google Scholar
• Rietberg MB, Van Wegen EE, Kwakkel G. Measuring fatigue in patients with multiple sclerosis: reproducibility, responsiveness and concurrent validity of three Dutch self-report questionnaires. Disabil Rehabil 2010;32(22):1870-6
   PubMed Web of Science ®Google Scholar
• Heesen C, Schulz KH, Fiehler J, Correlates of cognitive dysfunction in multiple sclerosis. Brain Behav Immun 2010;24(7):1148-55
   PubMed Web of Science ®Google Scholar
• Weinges-Evers N, Brandt AU, Bock M, Correlation of self-assessed fatigue and alertness in multiple sclerosis. Mult Scler 2010;16(9):1134-40
   PubMed Web of Science ®Google Scholar
• Smedal T, Beiske AG, Glad SB, Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance. Eur J Neurol 2011;18(1):114-20
   PubMed Web of Science ®Google Scholar
• Attarian HP, Brown KM, Duntley SP, The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol 2004;61(4):525-8
   PubMedGoogle Scholar
• Veauthier C, Radbruch H, Gaede G, Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler 2011;17(5):613-22
   PubMed Web of Science ®Google Scholar
• Veauthier C, Paul F. Fatigue in multiple sclerosis: which patient should be referred to a sleep specialist? Mult Scler 2011; Epub ahead of print
   Google Scholar
• Kaminska M, Kimoff RJ, Schwartzman K, Trojan DA. Sleep disorders and fatigue in multiple sclerosis: evidence for association and interaction. J Neurol Sci 2011;302(1-2):7-13
   PubMed Web of Science ®Google Scholar
• Merkelbach S, Schulz H, Kolmel HW, Fatigue, sleepiness, and physical activity in patients with multiple sclerosis. J Neurol 2011;258(1):74-9
   PubMed Web of Science ®Google Scholar
• Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985;12(3):251-4
   PubMed Web of Science ®Google Scholar
• The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987;14(3):273-8
   PubMed Web of Science ®Google Scholar
• Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989;46(6):676-80
   PubMedGoogle Scholar
• Krupp LB, Coyle PK, Doscher C, Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995;45(11):1956-61
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43(1):88-97
   PubMed Web of Science ®Google Scholar
• Damian MS, Gerlach A, Schmidt F, Modafinil for excessive daytime sleepiness in myotonic dystrophy. Neurology 2001;56(6):794-6
   PubMed Web of Science ®Google Scholar
• Happe S, Pirker W, Sauter C, Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol 2001;248(7):632-4
   PubMed Web of Science ®Google Scholar
• Pack AI, Black JE, Schwartz JR, Matheson JK. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001;164(9):1675-81
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Zorzon M, Bosco A, Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler 1999;5(6):428-31
   PubMed Web of Science ®Google Scholar
• Kroencke DC, Lynch SG, Denney DR. Fatigue in multiple sclerosis: relationship to depression, disability, and disease pattern. Mult Scler 2000;6(2):131-6
   PubMed Web of Science ®Google Scholar
• Rammohan KW, Rosenberg JH, Lynn DJ, Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase II study. J Neurol Neurosurg Psychiatry 2002;72(2):179-83
   PubMed Web of Science ®Google Scholar
• Zifko UA, Rupp M, Schwarz S, Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002;249(8):983-7
   PubMed Web of Science ®Google Scholar
• Lange R, Volkmer M, Heesen C, Liepert J. Modafinil effects in multiple sclerosis patients with fatigue. J Neurol 2009;256(4):645-50
   PubMed Web of Science ®Google Scholar
• Stankoff B, Waubant E, Confavreux C, Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005;64(7):1139-43
   PubMed Web of Science ®Google Scholar
• Moller F, Poettgen J, Broemel F, HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis. Mult Scler 2011;17(8):1002-9
   PubMed Web of Science ®Google Scholar
• Questions and answers on the review of medicines containing modafinil European Medical Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Modafinil_31/WC500099177.pdf [Last accessed 3 August 2011]
   Google Scholar
• Weinshenker BG, Penman M, Bass B, A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992;42(8):1468-71
   PubMed Web of Science ®Google Scholar
• Branas P, Jordan R, Fry-Smith A, Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 2000;4(27):1-61
   PubMedGoogle Scholar
• Bever CT Jr, Anderson PA, Leslie J, Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996;47(6):1457-62
   PubMed Web of Science ®Google Scholar
• Sheean GL, Murray NM, Rothwell JC, An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998;121(Pt 5):967-75
   PubMed Web of Science ®Google Scholar
• van Diemen HA, Polman CH, van Dongen TM, The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992;32(2):123-30
   PubMed Web of Science ®Google Scholar
• Solari A, Uitdehaag B, Giuliani G, Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2002(4):CD001330
   Google Scholar
• Van Diemen HA, Polman CH, Koetsier JC, 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993;16(3):195-204
   PubMed Web of Science ®Google Scholar
• Hayes KC, Katz MA, Devane JG, Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury. J Clin Pharmacol 2003;43(4):379-85
   PubMed Web of Science ®Google Scholar
• Hayes KC, Potter PJ, Hsieh JT, Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil 2004;85(1):29-34
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Edwards KR, A phase III trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 2010;68(4):494-502
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Krupp LB, Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009;373(9665):732-8
   PubMed Web of Science ®Google Scholar
• Goodman AD, Cohen JA, Cross A, Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007;13(3):357-68
   PubMed Web of Science ®Google Scholar
• Goodman AD, Brown TR, Cohen JA, Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008;71(15):1134-41
   PubMed Web of Science ®Google Scholar
• US Food and Drug Adiministration, Department of Health and Human Services, NDA Approval 022250. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022250s000ltr.pdf [Last accessed 29 November 2011]
   Google Scholar
• Summary of opinion (initial authorisation) Fampyra (fampridine). European Medical Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002097/WC500106531.pdf [Last accessed 3 August 2011]
   Google Scholar
• Feinstein A. Multiple sclerosis and depression. Mult Scler 2011;17(11):1276-81
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Benarroch EE, O’Brien PC, A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology 2005;64(7):1267-9
   PubMed Web of Science ®Google Scholar
• Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005;4(10):643-52
   PubMed Web of Science ®Google Scholar
• Freeman JA, Langdon DW, Hobart JC, Thompson AJ. Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 1999;52(1):50-6
   PubMed Web of Science ®Google Scholar
• Kidd D, Thompson AJ. Prospective study of neurorehabilitation in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62(4):423-4
   PubMed Web of Science ®Google Scholar
• Carey RG, Seibert JH, Posavac EJ. Who makes the most progress in inpatient rehabilitation? An analysis of functional gain. Arch Phys Med Rehabil 1988;69(5):337-43
   PubMed Web of Science ®Google Scholar
• Andreasen A, Stenager E, Dalgas U. The effect of exercise therapy on fatigue in multiple sclerosis. Mult Scler 2011;17(9):1041-54
   Web of Science ®Google Scholar
• Petajan JH, Gappmaier E, White AT, Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996;39(4):432-41
   PubMed Web of Science ®Google Scholar
• Mostert S, Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 2002;8(2):161-8
   PubMed Web of Science ®Google Scholar
• van den Berg M, Dawes H, Wade DT, Treadmill training for individuals with multiple sclerosis: a pilot randomised trial. J Neurol Neurosurg Psychiatry 2006;77(4):531-3
   PubMed Web of Science ®Google Scholar
• Oken BS, Kishiyama S, Zajdel D, Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology 2004;62(11):2058-64
   PubMed Web of Science ®Google Scholar
• Cakt BD, Nacir B, Genc H, Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil 2010;89(6):446-57
   PubMed Web of Science ®Google Scholar
• Mori F, Ljoka C, Magni E, Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol 2011;258(7):1281-7
   PubMed Web of Science ®Google Scholar
• Schwid SR, Petrie MD, Murray R, NASA/MS Cooling Study Group. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 2003;60(12):1955-60
   PubMed Web of Science ®Google Scholar
• Mathiowetz VG, Finlayson ML, Matuska KM, Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Mult Scler 2005;11(5):592-601
   PubMed Web of Science ®Google Scholar
• Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46(10):1121-3
   PubMed Web of Science ®Google Scholar
• Fisk JD, Ritvo PG, Ross L, Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 1994;18(Suppl 1):S79-83
   PubMed Web of Science ®Google Scholar
• Iriarte J, Katsamakis G, de Castro P. The Fatigue Descriptive Scale (FDS): a useful tool to evaluate fatigue in multiple sclerosis. Mult Scler 1999;5(1):10-16
   PubMed Web of Science ®Google Scholar
• Penner IK, Raselli C, Stocklin M, The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler 2009;15(12):1509-17
   PubMed Web of Science ®Google Scholar